JP2006509752A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006509752A5 JP2006509752A5 JP2004554318A JP2004554318A JP2006509752A5 JP 2006509752 A5 JP2006509752 A5 JP 2006509752A5 JP 2004554318 A JP2004554318 A JP 2004554318A JP 2004554318 A JP2004554318 A JP 2004554318A JP 2006509752 A5 JP2006509752 A5 JP 2006509752A5
- Authority
- JP
- Japan
- Prior art keywords
- component
- chloride
- composition according
- ethyl
- methylethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 6
- -1 2- (2,3-dihydrobenzofuran-5-yl) -1-methylethyl Chemical group 0.000 claims 5
- 206010069632 Bladder dysfunction Diseases 0.000 claims 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 206010046543 Urinary incontinence Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- QPCVHQBVMYCJOM-UHFFFAOYSA-N Propiverine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCCC)C(=O)OC1CCN(C)CC1 QPCVHQBVMYCJOM-UHFFFAOYSA-N 0.000 claims 3
- 229960002016 oxybutynin chloride Drugs 0.000 claims 3
- 229960003510 propiverine Drugs 0.000 claims 3
- ZKNJEOBYOLUGKJ-ALCCZGGFSA-N (z)-2-propylpent-2-enoic acid Chemical compound CCC\C(C(O)=O)=C\CC ZKNJEOBYOLUGKJ-ALCCZGGFSA-N 0.000 claims 2
- 206010020853 Hypertonic bladder Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010053236 Mixed incontinence Diseases 0.000 claims 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 2
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims 2
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims 2
- DMEPDNFRHUGNPT-UHFFFAOYSA-N [5-(diethylamino)-2-methylpent-3-yn-2-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C=1C=CC=CC=1C(O)(C(=O)OC(C)(C)C#CCN(CC)CC)C1CCCCC1 DMEPDNFRHUGNPT-UHFFFAOYSA-N 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 claims 2
- 229960002677 darifenacin Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003149 muscarinic antagonist Substances 0.000 claims 2
- 208000020629 overactive bladder Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229960003855 solifenacin Drugs 0.000 claims 2
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 claims 2
- 208000022170 stress incontinence Diseases 0.000 claims 2
- 229950000334 temiverine Drugs 0.000 claims 2
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 claims 2
- 229960004045 tolterodine Drugs 0.000 claims 2
- 206010046494 urge incontinence Diseases 0.000 claims 2
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 claims 2
- OTHYPAMNTUGKDK-UHFFFAOYSA-N (3-acetylphenyl) acetate Chemical compound CC(=O)OC1=CC=CC(C(C)=O)=C1 OTHYPAMNTUGKDK-UHFFFAOYSA-N 0.000 claims 1
- CXDSZFRIMJUZKT-MRGWGSTCSA-N (4r,5s)-5-[[(e,2r,3r)-3-(1,3-benzodioxol-5-yl)-6-(1,3-benzoxazol-2-yl)hex-5-en-2-yl]-(naphthalen-2-ylmethyl)carbamoyl]-1,3-dioxolane-2,2,4-tricarboxylic acid Chemical compound C=1C=C2C=CC=CC2=CC=1CN([C@@H]([C@H](C\C=C\C=1OC2=CC=CC=C2N=1)C=1C=C2OCOC2=CC=1)C)C(=O)[C@H]1OC(C(O)=O)(C(O)=O)O[C@H]1C(O)=O CXDSZFRIMJUZKT-MRGWGSTCSA-N 0.000 claims 1
- AYOYFVLAAQPHJT-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-[2-(6,7-dimethyl-3,4-dihydronaphthalen-2-yl)ethyl]pyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.C=1C=2C=C(C)C(C)=CC=2CCC=1CCN1CCCC1 AYOYFVLAAQPHJT-WLHGVMLRSA-N 0.000 claims 1
- ZUBLNWRGQSNWGQ-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-4-yl n-(2-phenylphenyl)carbamate;hydrochloride Chemical compound Cl.C1CN(CC2)CCC12OC(=O)NC1=CC=CC=C1C1=CC=CC=C1 ZUBLNWRGQSNWGQ-UHFFFAOYSA-N 0.000 claims 1
- DXPNKUPZWZIRSS-UHFFFAOYSA-N 4,4-diphenylcyclopent-2-en-1-amine;hydrochloride Chemical compound Cl.C1=CC(N)CC1(C=1C=CC=CC=1)C1=CC=CC=C1 DXPNKUPZWZIRSS-UHFFFAOYSA-N 0.000 claims 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 claims 1
- 241001553014 Myrsine salicina Species 0.000 claims 1
- RNGHAJVBYQPLAZ-UHFFFAOYSA-N Terodiline hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)NC(C)(C)C)C1=CC=CC=C1 RNGHAJVBYQPLAZ-UHFFFAOYSA-N 0.000 claims 1
- RVCSYOQWLPPAOA-CVPHZBIISA-M [(5s)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride Chemical compound [Cl-].[N+]12([C@H]3CCC2CC(C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 RVCSYOQWLPPAOA-CVPHZBIISA-M 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 claims 1
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 claims 1
- XXRMYXBSBOVVBH-UHFFFAOYSA-N bethanechol chloride Chemical compound [Cl-].C[N+](C)(C)CC(C)OC(N)=O XXRMYXBSBOVVBH-UHFFFAOYSA-N 0.000 claims 1
- 229960002123 bethanechol chloride Drugs 0.000 claims 1
- GUBNMFJOJGDCEL-UHFFFAOYSA-N dicyclomine hydrochloride Chemical compound [Cl-].C1CCCCC1C1(C(=O)OCC[NH+](CC)CC)CCCCC1 GUBNMFJOJGDCEL-UHFFFAOYSA-N 0.000 claims 1
- 229940110321 dicyclomine hydrochloride Drugs 0.000 claims 1
- 229960002236 emepronium Drugs 0.000 claims 1
- JEJBJBKVPOWOQK-UHFFFAOYSA-N emepronium Chemical compound C=1C=CC=CC=1C(CC(C)[N+](C)(C)CC)C1=CC=CC=C1 JEJBJBKVPOWOQK-UHFFFAOYSA-N 0.000 claims 1
- DCCSDBARQIPTGU-HSZRJFAPSA-N fesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C(C)C)=CC=CC=C1 DCCSDBARQIPTGU-HSZRJFAPSA-N 0.000 claims 1
- 229960002978 fesoterodine Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229960001550 hyoscyamine sulfate Drugs 0.000 claims 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 1
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 claims 1
- 229960002102 imipramine hydrochloride Drugs 0.000 claims 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims 1
- 229960001888 ipratropium Drugs 0.000 claims 1
- 229960005434 oxybutynin Drugs 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 229960001491 trospium Drugs 0.000 claims 1
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 claims 1
- 229960001530 trospium chloride Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02026546A EP1424079A1 (en) | 2002-11-27 | 2002-11-27 | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| PCT/EP2003/012331 WO2004047838A2 (de) | 2002-11-27 | 2003-11-05 | Pharmazeutische zusammensetzung aus beta-3-adrenozeptor-agonisten und antimuskarinika |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006509752A JP2006509752A (ja) | 2006-03-23 |
| JP2006509752A5 true JP2006509752A5 (enExample) | 2006-12-21 |
Family
ID=32241298
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004554308A Pending JP2006509751A (ja) | 2002-11-27 | 2003-11-03 | β−３アドレナリン受容体アゴニストとセロトニン及び／又はノルエピネフリン再取り込み阻害剤とを含む医薬組成物 |
| JP2004554318A Pending JP2006509752A (ja) | 2002-11-27 | 2003-11-05 | β−３アドレナリン受容体アゴニスト及び抗ムスカリン作用薬を含む医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004554308A Pending JP2006509751A (ja) | 2002-11-27 | 2003-11-03 | β−３アドレナリン受容体アゴニストとセロトニン及び／又はノルエピネフリン再取り込み阻害剤とを含む医薬組成物 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20090012161A9 (enExample) |
| EP (4) | EP1424079A1 (enExample) |
| JP (2) | JP2006509751A (enExample) |
| KR (1) | KR20050088295A (enExample) |
| CN (1) | CN1717230A (enExample) |
| AT (1) | ATE399005T1 (enExample) |
| AU (2) | AU2003285312A1 (enExample) |
| BR (1) | BR0316535A (enExample) |
| CA (2) | CA2507266A1 (enExample) |
| CO (1) | CO5580754A2 (enExample) |
| DE (1) | DE50310046D1 (enExample) |
| EA (1) | EA009781B1 (enExample) |
| EC (1) | ECSP055814A (enExample) |
| ES (1) | ES2309371T3 (enExample) |
| HR (1) | HRP20050467A2 (enExample) |
| MX (1) | MXPA05005483A (enExample) |
| NO (1) | NO20053088L (enExample) |
| PL (1) | PL376259A1 (enExample) |
| RS (1) | RS20050392A (enExample) |
| UA (1) | UA81931C2 (enExample) |
| WO (2) | WO2004047830A2 (enExample) |
| ZA (1) | ZA200503282B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7704527B2 (en) * | 2002-10-25 | 2010-04-27 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
| KR20060124603A (ko) * | 2003-11-03 | 2006-12-05 | 베링거 인겔하임 인터내셔날 게엠베하 | 베타-3-아드레날린 수용체 효능제 및 알파 길항제 및/또는5-알파-리덕타제 억제제를 함유하는 약제학적 조성물 |
| DE10356112A1 (de) * | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff |
| EP1804778A1 (de) * | 2004-10-18 | 2007-07-11 | Boehringer Ingelheim International GmbH | Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts |
| US20090247781A1 (en) * | 2004-10-26 | 2009-10-01 | Kissei Pharmaceutical Co., Ltd. | Synthesis of phenoxyacetic acid derivatives |
| US20090131469A1 (en) * | 2005-02-25 | 2009-05-21 | Astellas Pharma Inc. | Pharmaceutical agent comprising solifenacin |
| US20060165776A1 (en) * | 2005-08-31 | 2006-07-27 | Ramesh Sesha | Antidepressant oral pharmaceutical compositions |
| EP1769792A1 (de) * | 2005-09-30 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co.KG | Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden |
| US9440003B2 (en) * | 2005-11-04 | 2016-09-13 | Boston Scientific Scimed, Inc. | Medical devices having particle-containing regions with diamond-like coatings |
| FR2895259B1 (fr) * | 2005-12-22 | 2008-02-22 | Urosphere Sas | Methodes de traitement des incontinences urinaires |
| US20100172988A1 (en) * | 2006-01-10 | 2010-07-08 | Kissei Pharmaceutical Co., Ltd. | Sustained release preparation and method for production thereof |
| US20070292511A1 (en) * | 2006-05-22 | 2007-12-20 | Gershon Kolatkar | Duloxetine hydrochloride delayed release formulations |
| US20090175935A1 (en) * | 2006-08-14 | 2009-07-09 | Torrent Research Ltd. | Pharmaceutical compositions of duloxetine |
| EP1947103A1 (en) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments |
| US20080226711A1 (en) * | 2007-03-12 | 2008-09-18 | Torrent Pharmaceuticals Ltd. | Pharmaceutical compositions of duloxetine |
| WO2009066181A2 (en) * | 2007-07-09 | 2009-05-28 | Combino Pharm, S.L. | Oral delayed-release duloxentine hydrochloride pellets |
| PT2216021E (pt) | 2007-11-02 | 2012-11-06 | Astellas Pharma Inc | Composição farmacêutica para tratar uma bexiga hiperactiva |
| TWI478712B (zh) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
| ES2376095B1 (es) * | 2008-10-02 | 2013-01-24 | Laboratorios Del Dr. Esteve, S.A. | Pellets entéricos de duloxetina. |
| WO2010053068A1 (ja) * | 2008-11-07 | 2010-05-14 | 大日本住友製薬株式会社 | 新規で有用な下部尿路症状治療剤 |
| EP2316432A1 (de) * | 2009-10-30 | 2011-05-04 | ratiopharm GmbH | Zusammensetzung enthaltend Fesoterodin und Ballaststoffe |
| EP2377525A1 (en) * | 2010-03-26 | 2011-10-19 | Laboratorios del Dr. Esteve S.A. | Duloxetine enteric pellets |
| TR201802207T4 (tr) | 2010-03-29 | 2018-03-21 | Astellas Pharma Inc | Kontrollü Salımlı Farmasötik Bileşim. |
| KR20180008918A (ko) * | 2010-08-03 | 2018-01-24 | 앨씨알엑스, 인크. | 과민성 방광 치료를 위한 베타-3 아드레날린 수용체 작용제 및 무스카린 수용체 길항제의 약학적 배합제 |
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
| KR20150020160A (ko) * | 2012-02-09 | 2015-02-25 | 앨씨알엑스, 인크. | 과민성 방광의 치료를 위한 무스카린 수용체 길항제 및 베타―3 아드레날린 수용체 작용제의 조합물 |
| MX379066B (es) * | 2012-09-18 | 2025-03-04 | Taris Biomedical Llc | Sistemas de administracion de farmaco y metodos para el tratamiento de la disfuncion miccional de la vejiga y otros trastornos del tracto urinario inferior. |
| PL224543B1 (pl) | 2013-08-21 | 2017-01-31 | Pabianickie Zakłady Farm Polfa Spółka Akcyjna | Dojelitowa tabletka duloksetyny |
| CN107205964A (zh) | 2014-12-03 | 2017-09-26 | 威力塞帕特治疗股份有限公司 | 使用调节释放索拉贝隆用于下尿路症状的组合物和方法 |
| JP2018536453A (ja) * | 2015-10-15 | 2018-12-13 | デューク ユニバーシティ | 膀胱機能障害を処置するための状態依存的末梢神経調節 |
| WO2017070689A2 (en) | 2015-10-23 | 2017-04-27 | Velicept Therapeutics, Inc. | Solabegron zwitterion and uses thereof |
| WO2017186598A1 (en) | 2016-04-25 | 2017-11-02 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
| US20190307696A1 (en) | 2016-04-25 | 2019-10-10 | Synthon B.V. | Tablets comprising mirabegron and solifenacin |
| US10478399B2 (en) | 2017-10-12 | 2019-11-19 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
| US12097189B1 (en) | 2024-02-09 | 2024-09-24 | Astellas Pharma Inc. | Pharmaceutical composition for modified release |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4956388A (en) * | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
| PH30083A (en) * | 1991-02-25 | 1996-12-27 | Lilly Co Eli | Treatment of lower urinary tract disorders |
| IL104567A (en) * | 1992-02-03 | 1997-03-18 | Fujisawa Pharmaceutical Co | Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
| TW344661B (en) * | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
| US6262115B1 (en) * | 1995-05-22 | 2001-07-17 | Alza Coporation | Method for the management of incontinence |
| AU715216B2 (en) * | 1995-10-26 | 2000-01-20 | Mitsubishi-Tokyo Pharmaceuticals, Inc. | Phenylethanolamine compounds useful as beta3 agonist, process for producing the same, and intermediates in the production of the same |
| CA2242351C (en) * | 1996-01-10 | 2003-03-11 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel tricyclic compounds and drug compositions containing the same |
| WO1997033880A1 (en) * | 1996-03-11 | 1997-09-18 | Eli Lilly And Company | Methods of treating or preventing interstitial cystitis |
| WO1998003067A1 (en) * | 1996-07-19 | 1998-01-29 | Gunnar Aberg | S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders |
| KR20000068208A (ko) * | 1996-08-19 | 2000-11-25 | 간자와 무츠와 | 빈뇨 및 요실금의 예방·치료제 |
| WO1998021184A1 (en) * | 1996-11-14 | 1998-05-22 | Pfizer Inc. | Process for substituted pyridines |
| WO1998022480A1 (en) * | 1996-11-18 | 1998-05-28 | Smithkline Beecham Plc | Phosphorus containing aryloxy or arylthio propanolamine derivatives |
| JPH1112171A (ja) * | 1997-06-19 | 1999-01-19 | Nisshin Flour Milling Co Ltd | 消化器疾患治療薬 |
| ID24062A (id) * | 1997-07-25 | 2000-07-06 | Kissei Pharmaceutical | Turunan-turunan asam aminoetilfenoksiasetat dan obat untuk mengurangi nyeri dan membantu penyingkiran dalam litiasis saluran air kencing |
| DK1028111T3 (da) * | 1997-10-17 | 2004-09-20 | Yamanouchi Pharma Co Ltd | Amidderivater eller salte heraf |
| NZ505103A (en) * | 1997-12-18 | 2003-03-28 | Kissei Pharmaceutical | Phenylaminoalkylcarboxylic acid derivatives useful as beta 3 adrenoceptor stimulants |
| US6319920B1 (en) * | 1998-02-27 | 2001-11-20 | Syntex (U.S.A.) Llc | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives |
| WO1999051564A1 (en) * | 1998-04-06 | 1999-10-14 | Fujisawa Pharmaceutical Co., Ltd. | Propanolamine derivatives |
| EP1072583B1 (en) * | 1998-04-14 | 2004-09-01 | Kissei Pharmaceutical Co., Ltd. | 2-methylpropionic acid derivatives and medicinal compositions containing the same |
| EP0957073A1 (en) * | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
| MY126489A (en) * | 1998-07-08 | 2006-10-31 | Kissei Pharmaceutical | Phenoxyacetic acid derivatives and medicinal compositions containing the same |
| SI1039882T1 (sl) * | 1998-08-27 | 2011-01-31 | Pfizer Health Ab | Terapevtska formulacija za dajanje tolterodina s kontroliranim sproščanjem |
| DE19932651A1 (de) * | 1999-07-13 | 2001-01-18 | Hexal Ag | Transdermales therapeutisches System zur Anwendung von Tolterodin |
| EP1078924B1 (en) * | 1999-07-23 | 2004-10-20 | Pfizer Products Inc. | Intermediates and a process for producing beta-adrenergic receptor agonists |
| PT1227806E (pt) * | 1999-11-11 | 2005-10-31 | Pfizer Health Ab | Formulacao farmaceutica contendo tolterodina e sua utilizacao |
| US6562368B2 (en) * | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers |
| SE9904850D0 (sv) * | 1999-12-30 | 1999-12-30 | Pharmacia & Upjohn Ab | Novel process and intermediates |
| CA2398199A1 (en) * | 2000-01-28 | 2001-08-02 | Asahi Kasei Kabushiki Kaisha | Novel therapeutic agents that use a .beta.3 agonist |
| CN1396829A (zh) * | 2000-02-24 | 2003-02-12 | 法玛西雅厄普约翰美国公司 | 新的药物联合形式 |
| DE60045082D1 (de) * | 2000-06-07 | 2010-11-18 | Watson Pharmaceuticals Inc | Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin |
| US6514991B2 (en) * | 2000-07-17 | 2003-02-04 | Wyeth | Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists |
| MXPA03006003A (es) * | 2001-01-02 | 2005-09-08 | Upjohn Co | Nuevas combinaciones de farmacos. |
| GB0102408D0 (en) * | 2001-01-31 | 2001-03-14 | Glaxo Group Ltd | Chemical compounds |
| EP1236723A1 (en) * | 2001-03-01 | 2002-09-04 | Pfizer Products Inc. | Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof |
| WO2002085871A2 (en) * | 2001-04-04 | 2002-10-31 | Wyeth | Serotonergic agents with long-acting in vivo effects |
| WO2003035600A1 (en) * | 2001-10-19 | 2003-05-01 | Fujisawa Pharmaceutical Co., Ltd. | Process for producing benzocycloheptene derivative |
| US20030144352A1 (en) * | 2001-11-05 | 2003-07-31 | Cammarata Sue K. | Antimuscarinic aerosol |
| JP2005526040A (ja) * | 2002-02-19 | 2005-09-02 | ファルマシア・コーポレーション | 失禁の治療のためのシクロオキシゲナーゼ阻害剤及び抗ムスカリン剤の使用 |
-
2002
- 2002-11-27 EP EP02026546A patent/EP1424079A1/en not_active Withdrawn
-
2003
- 2003-03-11 UA UAA200506227A patent/UA81931C2/uk unknown
- 2003-11-03 CN CNA2003801044257A patent/CN1717230A/zh active Pending
- 2003-11-03 ES ES03778298T patent/ES2309371T3/es not_active Expired - Lifetime
- 2003-11-03 CA CA002507266A patent/CA2507266A1/en not_active Abandoned
- 2003-11-03 MX MXPA05005483A patent/MXPA05005483A/es not_active Application Discontinuation
- 2003-11-03 PL PL03376259A patent/PL376259A1/xx unknown
- 2003-11-03 JP JP2004554308A patent/JP2006509751A/ja active Pending
- 2003-11-03 EP EP03778298A patent/EP1572181B1/de not_active Expired - Lifetime
- 2003-11-03 DE DE50310046T patent/DE50310046D1/de not_active Expired - Fee Related
- 2003-11-03 EA EA200500776A patent/EA009781B1/ru not_active IP Right Cessation
- 2003-11-03 AU AU2003285312A patent/AU2003285312A1/en not_active Abandoned
- 2003-11-03 HR HR20050467A patent/HRP20050467A2/xx not_active Application Discontinuation
- 2003-11-03 AT AT03778298T patent/ATE399005T1/de not_active IP Right Cessation
- 2003-11-03 RS RSP-2005/0392A patent/RS20050392A/sr unknown
- 2003-11-03 WO PCT/EP2003/012225 patent/WO2004047830A2/de not_active Ceased
- 2003-11-03 KR KR1020057009414A patent/KR20050088295A/ko not_active Withdrawn
- 2003-11-03 BR BR0316535-3A patent/BR0316535A/pt not_active IP Right Cessation
- 2003-11-03 EP EP05027827A patent/EP1640000A3/de not_active Withdrawn
- 2003-11-05 EP EP03782183A patent/EP1567149A2/de not_active Withdrawn
- 2003-11-05 CA CA002507343A patent/CA2507343A1/en not_active Abandoned
- 2003-11-05 WO PCT/EP2003/012331 patent/WO2004047838A2/de not_active Ceased
- 2003-11-05 AU AU2003289854A patent/AU2003289854A1/en not_active Abandoned
- 2003-11-05 JP JP2004554318A patent/JP2006509752A/ja active Pending
-
2005
- 2005-04-22 ZA ZA200503282A patent/ZA200503282B/en unknown
- 2005-05-23 EC EC2005005814A patent/ECSP055814A/es unknown
- 2005-05-24 US US11/136,165 patent/US20090012161A9/en not_active Abandoned
- 2005-05-24 US US11/136,148 patent/US20050261328A1/en not_active Abandoned
- 2005-06-23 NO NO20053088A patent/NO20053088L/no not_active Application Discontinuation
- 2005-06-27 CO CO05062906A patent/CO5580754A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006509752A5 (enExample) | ||
| JP2006509751A5 (enExample) | ||
| RU2404771C3 (ru) | Комбинации, содержащие антимускариновые средства и бета-адренергические агонисты | |
| US20050261328A1 (en) | Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents | |
| ES2315425T3 (es) | Compuestos de amonio cuaternario y su uso como agentes antimuscarinicos. | |
| US10813890B2 (en) | Pharmaceutical combination | |
| US20030199582A1 (en) | Tolterodine salts | |
| SG184387A1 (en) | Methods of improving quality of sleep | |
| JP2023143940A5 (enExample) | ||
| KR20040044953A (ko) | 요실금 치료를 위한, 무스카린 길항제와 선택된오피오이드와의 배합물 | |
| MXPA04003806A (es) | Aerosol antimuscarinico. | |
| JP5792067B2 (ja) | αアドレナリン受容体拮抗薬と抗ムスカリン薬の併用 | |
| US20050119239A1 (en) | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and an active substance which influences prostaglandin metabolism | |
| RU2008112176A (ru) | Профилактическое или терапевтическое средство для заболевания, вызванного уменьшением количества слезной жидкости | |
| MXPA06004625A (es) | Composicion famaceutica que contiene un agonista de un adrenoceptor beta-3 y un antagonista alfa y/o un inhibidor de la 5-alfa-reductasa. | |
| JP2007509897A (ja) | β−３−アドレノセプターアゴニスト及びα−アゴニストから成る医薬組成物 | |
| US20070078181A1 (en) | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | |
| JP2005503424A (ja) | 尿疾患の治療用医薬組成物 | |
| WO2003002059A2 (en) | Tolterodine metabolites | |
| CN1518444B (zh) | 取代的6-二甲基氨基甲基-1-苯基环己烷化合物在制备治疗尿失禁的药物中的用途 | |
| US20080167317A1 (en) | Combination Therapy | |
| EP3513787A1 (en) | Use of beta-adrenergic inverse agonists for smoking cessation | |
| HK1085917A (en) | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor |